Showing 391-400 of 1779 results for "".
Caught In The Middle
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/caught-in-the-middle/20665/Understanding how RF microneedling fits into today's cosmetic practice.A Case of Deductible Reasoning and Social Media Extortion
https://practicaldermatology.com/topics/practice-management/a-case-of-deductible-reasoning-and-social-media-extortion/21201/Lichen Amyloidosis
https://practicaldermatology.com/topics/skin-cancer-photoprotection/lichen-amyloidosis/20681/New Products
https://practicaldermatology.com/columns/new-products/new-products-14/24015/Three's the Charm
https://practicaldermatology.com/topics/practice-management/threes-the-charm/20585/Expert injectors discuss the promise and perils of Botox Cosmetic's third nod.Take 5: Recent Developments in Systemic Therapy for Psoriasis
https://practicaldermatology.com/columns/recent-developments/take-5-recent-developments-in-systemic-therapy-for-psoriasis/22002/New data reveal noteworthy financial and clinical trends in the use of systemic agents.Medical Costs Skyrocket and New York Times Reporter Finds a Scapegoat
https://practicaldermatology.com/topics/practice-management/medical-costs-skyrocket-and-emnew-york-timesem-reporter-finds-a-scapegoat/21404/Take 5: Innovations in Aesthetic Treatments
https://practicaldermatology.com/columns/take-5/take-5-innovations-in-aesthetic-treatments/21746/Five new or emerging products may expand skin rejuvenation options.DermWireTV: Derm Salaries Down, Allergan Eyes Soliton, Emsculpt Week
https://practicaldermatology.com/topics/practice-management/dermwiretv-derm-salaries-down-allergan-eyes-soliton-emsculpt-week/19941/Just under half of all physicians in the US are employed in physician-owned medical practices, new data from the American Medical Association show. Medscape’s annual Physician Compensation Report reveals that physicians overall saw a reduction in income due to the COVID-19 pandemic; income for dermDermWireTV: Sotyktu Approval, Cetaphil at 75, Psoriasis/Depression Link
https://practicaldermatology.com/topics/psoriasis/dermwiretv-sotyktu-approval-cetaphil-at-75-psoriasisdepression-link/20138/FDA has approved Bristol Myers Squibb’s Sotyktu (deucravacitinib) for the oral treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. April Armstrong, MD discusses the first TYK-2 inhibitor approved for psoriasis. As Cetaphil (Galderma)